Scholarlink

<p>Disulfidptosis, a newly identified form of programmed cell death (PCD) that was discovered in 2023, occurs specifically in cells with high <i>SLC7A11</i> expression when glucose is scarce. The underlying mechanism involves NADPH depletion, which triggers severe disulfide stress and ultimately causes the actin cytoskeleton to collapse. In recent years, researchers have increasingly focused on the potential role of disulfidptosis in liver diseases. Current evidence mainly supports its involvement in hepatocellular carcinoma (HCC), with some preliminary data also suggesting connections to liver cirrhosis and metabolic liver disorders. This review critically synthesizes the molecular mechanisms underlying disulfidptosis, explores its possible links to various liver conditions based on the available evidence, and assesses the potential of disulfidptosis-related genes (<i>DRGs</i>) as exploratory tools for diagnosis, prognostic stratification, and exploratory therapeutic prediction. Together, these insights provide a foundation for understanding liver disease pathogenesis and may guide future research efforts, pending rigorous experimental and clinical validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Disulfidptosis in hepatocellular carcinoma: molecular mechanisms, therapeutic potential, and exploratory insights into chronic liver diseases

  • 期刊论文

  • 发表日期：

    2026年5月24日

查看全文
  • Yuting Liu,
  • Wenzhuo Hu,
  • Jingyin Mai,
  • Yang Cheng

摘要

Disulfidptosis, a newly identified form of programmed cell death (PCD) that was discovered in 2023, occurs specifically in cells with high SLC7A11 expression when glucose is scarce. The underlying mechanism involves NADPH depletion, which triggers severe disulfide stress and ultimately causes the actin cytoskeleton to collapse. In recent years, researchers have increasingly focused on the potential role of disulfidptosis in liver diseases. Current evidence mainly supports its involvement in hepatocellular carcinoma (HCC), with some preliminary data also suggesting connections to liver cirrhosis and metabolic liver disorders. This review critically synthesizes the molecular mechanisms underlying disulfidptosis, explores its possible links to various liver conditions based on the available evidence, and assesses the potential of disulfidptosis-related genes (DRGs) as exploratory tools for diagnosis, prognostic stratification, and exploratory therapeutic prediction. Together, these insights provide a foundation for understanding liver disease pathogenesis and may guide future research efforts, pending rigorous experimental and clinical validation.